Developing a Coronavirus Vaccine Using Allogeneic Cell Based Therapy with Jeff Wolf Heat Biologics
Jeff Wolf, CEO, Heat Biologics describes the vaccine platform Heat has developed originally for oncology and their licensing agreement with the University of Miami to use the same vaccine approach for NIH-funded studies against Zika, malaria, and HIV against the Coronavirus.
Woman of the Week Podcast
Smital Shah shares the lessons she learned as a financial strategist and investment banker, which she is now using to help guide ProQR, a rare disease company, to bring much-needed treatments to patients.
Nimble Supply Chains Minimize Disruption
Two marine cargo terminals in Seattle closed Friday (and will close each Friday in the foreseeable future), along with one in Baltimore that will be closed until Tuesday. Cargo volume from Asia that entered the U.S.at the Port of Los Angeles plummeted nearly 23% in the past 30 days. Next door, the Port of Long Beach reported a nearly 10% drop in its incoming Asian cargo.
Aligos tackles hepatitis B with combo approach, three drugs entering clinic this year
Lessons learned from development of hepatitis C therapies could be applied to the underserved hepatitis B population, potentially leading to a functional cure through a combination of optimized drugs that attack the virus from different angles. That is the mission of 2-year-old Aligos Therapeutics Inc., a South San Francisco-based startup focused on liver-related diseases.
Partnered with Gilead and Sanofi, protein degradation specialist Nurix bags $120M to chart its own clinical path
On the same day that Cambridge, MA-based Kymera Therapeutics unveiled a $102 million round to enter into development phase, Nurix said it has raised $120 million to do the same out of San Francisco’s Mission Bay.
After Kymera’s raise, Nurix nabs $120M as it too hones in on clinical work
Sanofi- and Gilead Sciences-backed Nurix Therapeutics is following suit with rival biotech Kymera in raising a major cash haul for its protein modulation R&D work. Nurix has grabbed $120 million to push on with its drug discovery platform that focuses on manipulating the ubiquitin system, which breaks down damaged or unneeded proteins.
Genetic testing hopes to speed up drug development in rare eye diseases
When it comes to fighting rare diseases, the biggest barrier to overcome is often the lack of knowledge around the condition. A free genetic test is hoping to combat this and speed up drug development in inherited retinal diseases.
Motus GI moving headquarters from Florida to Massachusetts
Motus GI is moving its corporate headquarters from Fort Lauderdale, Fla., to the greater Boston area in the second quarter of this year to support commercial efforts for its Pure-Vu colon cleansing system. The new headquarters will be in Norwood, Mass., closer to major medical device hubs, giving the company access to a bigger talent pool. Norwood is about 25 miles south of Boston.
